JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikolaus, S.
Right arrow Articles by Müller, H.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikolaus, S.
Right arrow Articles by Müller, H.-W.
Journal of Nuclear Medicine Vol. 44 No. 4 618-624
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

In Vivo Measurement of D2 Receptor Density and Affinity for 18F-(3-N-Methyl)Benperidol in the Rat Striatum with a PET System for Small Laboratory Animals

Susanne Nikolaus, PhD1, Rolf Larisch, MD1, Markus Beu, BSc1, Karl Hamacher, PhD2, Farhad Forutan, BSc1, Henning Vosberg, MD1 and Hans-Wilhelm Müller, MD1

1 Nuklearmedizinische Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
2 Institut für Nuklearchemie, Forschungszentrum Jülich GmbH, Jülich, Germany

A recent investigation showed that intracerebral radioactivity concentrations can reliably be quantified in vivo with a small-animal PET device. The purpose of the current study was to investigate the binding characteristics of the D2 receptor radioligand 18F-(3-N-methyl)benperidol (18FMB) in rat striatum by determining receptor density (Bmax) and affinity (Kd) in vivo. For validation, Kd and Bmax additionally were determined in vitro using storage phosphor autoradiography. Methods: Striatal radioactivity was measured with PET in 8 Sprague-Dawley rats after injection of 18FMB in increasing specific activities. Free radioligand concentrations were estimated from cortical radioactivity concentrations and were subtracted from striatal radioactivity concentrations to obtain specific binding. In vitro saturation experiments were performed on 7 further rats according to the isotopic dilution method. Specific binding was determined by both subtraction of 18FMB binding in the presence of raclopride and subtraction of cortical radioactivity concentrations from total radioligand binding. Saturation binding curves were obtained by plotting specifically bound radioligand concentrations against free radioligand concentrations and were evaluated with regression analysis. Results: PET yielded a Kd of 6.2 nmol/L and a Bmax of 16 fmol/mg for the striatal D2 receptor. In vitro, Kd and Bmax amounted to 4.4 nmol/L and 84.1 fmol/mg (subtraction of 18FMB binding in the presence of raclopride), respectively, and 7.9 nmol/L and 70.1 fmol/mg (subtraction of cortical radioactivity concentrations), respectively. Conclusion: Kd values measured with PET and autoradiography agreed and corresponded to inhibition constants obtained in previous in vitro studies. Bmax values lay within the same order of magnitude. The results of in vitro saturation binding analyses also agreed, irrespective of the mode of determination of free radioligand concentrations. Thus, Bmax and Kd may be determined with PET in analogy to the evaluation of in vitro binding data by regression analysis of bound-versus-free ligand concentrations. Our results show that small-animal tomographs are valuable tools for the in vivo characterization of receptor radioligands as an alternative to autoradiography.

Key Words: 18F-(3-N-methyl)benperidol • dopamine D2 receptors • animal PET • autoradiography • saturation binding analysis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.